DCAT Announces New Board of Directors for 2022
By

The DCAT organization is pleased to announce the members of its Board of Directors for the upcoming fiscal year, November 1, 2021, to October 31, 2022. The members were interviewed and selected by the organization’s Leadership Development Committee and were approved by each Member Company’s Designated Delegate through balloting over the last several weeks.

EXECUTIVE COMMITTEE: BOARD OF DIRECTORS

Elected as President is Kerri McCullough Wood of Teva API, Teva Pharmaceuticals. Previously she served in the three Vice President positions. Joining Ms. McCullough on the Executive Committee will be Sally Macaluso of Johnson and Johnson, who previously served as Second Vice President/Finance Officer and Third Vice President. Ms. Macaluso will now become the First Vice President. Charles Davies, of Merck & Co. Inc., previously served as Third Vice President and will now serve as the Second Vice President/Finance Officer. Elected to the Executive Committee as the new Third Vice President is Donna GruolXGen Pharmaceuticals DJB. Ms. Gruol has previously served as a member of DCAT’s Advisory Council, Leadership Development Committee, Alliance for Industry Women Committee, and as Chairperson of the Member Advantage Committee.

DIRECTORS: BOARD OF DIRECTORS

Re-elected as Directors on the Board are Lori Hoffman of Piramal Critical CareGavin Murdoch of Thermo Fisher Scientific, and Scott Price of Ren-Pharm International. Newly elected as Directors for a one-year term are Craig Douglas of Siegfried-USA and Courtney Stanton of Smithfield BioScience.

IMMEDIATE PAST PRESIDENTS: BOARD OF DIRECTORS

Rounding out the eleven-person Board of Director members are the Immediate Past Presidents, Sean Diver of Lonza AG and Paolo Magri of Bioseutica.

Visit https://dcat.org/board/ to view the current Board of Directors.